主題重點

選擇性的設計、篩選、評估

變構激酶抑制劑的特定與分析

共享結合阻礙

中樞神經系適應的激酶：大課題

炎症與自體免疫—主要計畫

癌的激酶—PI3、mTOR、cMet等

追求新的激酶標的

DMPK、Tox的篩選與監測

電腦手法的進化

抵抗性—將來的課題

Click here for the preliminary agenda

著名的學術相關人員

Mark Ashwell, ArQule Inc

Peter Brandt, Beactica AB

Dirksen Bussiere, Novartis Vaccines & Diagnostics Inc.

Jean Cui, Pfizer, Inc.

Greg Cuny, Brigham & Women’s Hospital

David C. Dalgarno, ARIAD Pharmaceuticals Inc.

David H. Drewry, GlaxoSmithKline

Isabelle Dussault, Amgen

Doriano M. Fabbro, Novartis Institutes for BioMedical Research

Daniel Goldberg, Boehringer-Ingelheim Pharmaceuticals

Andrew C. Good, Genzyme Corp

John D. Haley, OSI Pharmaceuticals

Ronald Knegtel, Vertex Pharmaceuticals (Europe) Ltd.

Ravi G. Kurumbail, Pfizer, Inc.

Chris Liang, Xcovery, LLC

Carol MacKintosh, University of Dundee

Yibing Shan, D. E. Shaw Research

Juswinder Singh, Avila Therapeutics, Inc.

Rajinder Singh, Rigel Pharmaceuticals Inc.

Eli Wallace, Array BioPharma

Neil Wishart, Abbott

Paul Yu, Massachusetts General Hospital